Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Natural Killer T (NKT) cells are a unique subset of immune cells that share features of both T cells and natural killer (NK) cells. NKT cells have shown promise in cancer treatment due to their unique properties and functions, including broad tumor recognition, rapid immune response, and lower risk of graft-versus-host disease (GVHD). Due to their versatile functional attributes and ability to produce large amounts of cytokines, NKT cells have emerged as promising candidates for immunotherapy applications. Allogeneic NKT cells further enhance the therapeutic potential by providing an "off-the-shelf" treatment option, circumventing tumor evasion issues associated with autologous therapies.
Creative Biolabs is dedicated to offering a specialized CAR/TCR-NKT cell development service. Our advanced platforms are designed to leverage the therapeutic potential of NKT cells, providing tailored solutions for various research applications. Through our state-of-the-art technologies and dedicated research teams, we ensure the development of high-quality CAR-NKT and TCR-NKT cells, pushing the development of next-generation immunotherapies.
CAR-NKT cells are designed by incorporating genes encoding CARs into NKT cells using viral or non-viral transduction methods. At Creative Biolabs, we use precise genetic modification techniques, including CRISPR/Cas9 and lentiviral vectors, which allow for the stable integration and expression of CAR constructs in NKT cells. Our CAR-NKT development service includes target identification, CAR design, vector construction, and cell transduction. We also provide comprehensive validation and functional assays to ensure that the CAR-NKT cells exhibit the desired attributes, such as specificity, cytotoxicity, and cytokine production, essential for effective therapeutic outcomes. Additionally, our platform incorporates advanced techniques for cell expansion and activation, ensuring that sufficient quantities of CAR-NKT cells can be produced for further applications.
Creative Biolabs provides a comprehensive TCR-NKT cell development service that includes TCR discovery and validation, and genetic engineering. We employ advanced TCR optimization methods, including affinity maturation and specificity tuning, to enhance the binding affinity and selectivity of TCRs for their target antigens. Our TCR-NKT cell platform is characterized by its rigorous quality control measures, which include extensive phenotypic and functional characterization of engineered cells. Our platform also focuses on the efficient expansion of engineered cells while maintaining their functional integrity. Through optimized culture conditions and activation protocols, we ensure that TCR-NKT cells retain their proliferation capacity and effector functions, enabling robust in vivo anti-tumor responses.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
